fda tirzepatide shortage update today confirms is still over, gives compounders a grace period 2026 FDA Rules and News

Description IGF-1 LR3 1mg IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a synthetic analog of human Insulin-like Growth Factor-1 modified with two structural changes from native IGF-1: an arginine substitution at position 3 and an N-terminal extension of 13 amino acids

Here are a few ways future formulations could shift the market: Oral (Rybelsus 2.0, better semaglutide formulations) What changes: Easier to prescribe and adhere to, but worse tolerability Where it moves: Into primary care lower friction, tighter payer control Strategic shift: More access, same adherence problem Risk: Higher churn, more side-effect driven dropout Next-gen combos (e.g., GLP-1 + GIP + amylin, muscle-sparing) What changes: Better outcomes, better tolerability Where it moves : Into specialist-aligned care models deeper payer integration Strategic shift: Drugs become platforms unlock long-term value Risk: Slow coverage without strong RWE

Even though about 12% of American adults are already taking GLP-1 drugs, that portends a much bigger story ahead

Vitamin D toxicity is uncommon but can occur when very large doses are taken consistently over time

Evaluation of Dietary Niacin and New-Onset Hypertension Among Chinese Adults

Although cerebellar stimulation is not a new idea, its focus has changed over the years